On February 14, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) released the annual performance express of 2021. In 2021, Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) the operating revenue reached 5.75 billion yuan, an increase of 144.25% over the previous year; The net profit attributable to shareholders of listed companies was 2.016 billion yuan, a year-on-year increase of 197.83%. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 1.94 billion yuan, a year-on-year increase of 214.48%.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) said that the main factor affecting the operating performance is that the company’s bivalent cervical cancer vaccine continues to maintain booming production and sales, and the revenue and profit increase at a high speed; As the covid-19 pneumonia epidemic has not been effectively controlled, the demand for overseas testing has increased significantly, and the company’s covid-19 raw material sales and overseas testing reagent export revenue have increased rapidly.
The domestic bivalent HPV vaccine developed by Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) was approved for marketing in May 2020. It is the first domestic HPV product in China. At present, there are four HPV vaccines on the market in China, including the four valent and nine valent HPV vaccines of MSD, the bivalent HPV vaccine of GlaxoSmithKline and the bivalent HPV vaccine of Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) . According to the batch issuance data of the Central Inspection Institute, the batch issuance volume of Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) bivalent HPV vaccine in 2020 is 2.46 million, and the batch issuance volume in 2021 is expected to be about 10 million. Data show that the bivalent HPV vaccine in Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) in 2021 accounted for 37% of the four approved HPV vaccines issued in China.
Some analysts pointed out that the current market scale of HPV vaccine in China is far from reaching the peak. In the future, with sufficient supply and the approval of male indications of HPV vaccine in China, the sales volume of HPV vaccine in China will increase explosively.
Facing the broad market, at present, many enterprises in China are making layout. Recently, the results of the drug registration progress query of the State Food and drug administration were recently announced. The review and approval status of the listing application of Walvax Biotechnology Co.Ltd(300142) bivalent HPV vaccine has been updated to “under approval”, which means that the vaccine is expected to be officially approved in the near future. In addition, the HPV vaccines of Chengdu Sanle Pharmaceutical Co., Ltd. and Chengdu Xiaole Pharmaceutical Co., Ltd. have entered the HPV clinical stage, and the HPV vaccines of Chengdu Xiaole Pharmaceutical Co., Ltd. and Chengdu Xiaobo Pharmaceutical Co., Ltd. have entered the HPV clinical stage.
